InvestorsHub Logo
Followers 2094
Posts 90189
Boards Moderated 0
Alias Born 12/17/2011

Re: None

Tuesday, 07/27/2021 10:11:10 AM

Tuesday, July 27, 2021 10:11:10 AM

Post# of 8287
AIKI...86...Tue, July 27, 2021, 10:00 AM
AIkido's License to Technology Includes Targeted Psilocybin Treatment for Cancer Patients

NEW YORK, July 27, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/477,125. This technology relates to the use of novel and proprietary central nervous system (CNS) homing peptides. This technology has been exclusively sublicensed to AIkido Pharma for use of psilocybin for the therapeutic treatment of neuroinflammatory disease in cancer patients.

20% of life is what happens to you and 80% is how you react to what happens to you...